Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of sequential gemcitabine followed by docetaxel in elderly patients with advanced non-small cell lung cancer
2005-001260-31Phase 2Active
- Sponsor
- Azienda USL Toscana Nord Ovest
- Start
- Mar 2006
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine and docetaxel in non-small cell lung cancer (NSCLC), sponsored by Azienda USL Toscana Nord Ovest. Primary endpoint: Objective response rate. Started Mar 2006; status: active.
02
Drugs
gemcitabinedocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2005-001260-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001260-31.